EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Development of fluorine-substituted NH2-biphenyl-diarylpyrimidines as highly potent non-nucleoside reverse transcriptase inhibitors: Boosting the safety and metabolic stability

Xin Jin, Shuai Wang, Limin Zhao, Wenjuan Huang, Yinxiang Zhang, Christophe Pannecouque, Erik De Clercq, Ge Meng, Huri Piao, Fener Chen

Acta Pharmaceutica Sinica B · 2023-03 · 13 (3) · 1192-1203

DOI: 10.1016/j.apsb.2022.08.017 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Acta Pharmaceutica Sinica B, 2023-03. Verfasst von Xin Jin und 9 weiteren Autor:innen. Beteiligte Einrichtung: Engineering Center of Catalysis and Synthesis for Chiral Molecules, Department of Chemistry, Fudan University, Shanghai 200433, China. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Key Research and Development Program of China, National Natural Science Foundation of China, Fudan University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

Stichwörter der Autor:innen

DAPYsHIV-1Metabolic stabilityNNRTISafety

Autor:innen und Institutionen

  • Engineering Center of Catalysis and Synthesis for Chiral Molecules, Department of Chemistry, Fudan University, Shanghai 200433, China.
  • Shanghai Engineering Center of Industrial Asymmetric Catalysis for Chiral Drugs, Shanghai 200433, China.
  • Key Laboratory of Natural Resources of Changbai Mountain & Functional Molecules, Ministry of Education, College of Pharmacy, Yanbian University, Yanji 133002, China.
  • Rega Institute for Medical Research, KU Leuven, Leuven B-3000, Belgium.

Förderung

  • National Key Research and Development Program of China
  • National Natural Science Foundation of China
  • Fudan University

Zitieren

APA

Jin, X., Wang, S., Zhao, L., Huang, W., Zhang, Y., Pannecouque, C., De Clercq, E., Meng, G., Piao, H., & Chen, F. (2023). Development of fluorine-substituted NH2-biphenyl-diarylpyrimidines as highly potent non-nucleoside reverse transcriptase inhibitors: Boosting the safety and metabolic stability. Acta Pharmaceutica Sinica B, 13(3), 1192-1203. https://doi.org/10.1016/j.apsb.2022.08.017

Vancouver

Jin X, Wang S, Zhao L, Huang W, Zhang Y, Pannecouque C, et al. Development of fluorine-substituted NH2-biphenyl-diarylpyrimidines as highly potent non-nucleoside reverse transcriptase inhibitors: Boosting the safety and metabolic stability. Acta Pharmaceutica Sinica B. 2023;13(3):1192-1203. doi:10.1016/j.apsb.2022.08.017

BibTeX
@article{Jin2023,
  author = {Jin, Xin and Wang, Shuai and Zhao, Limin and Huang, Wenjuan and Zhang, Yinxiang and Pannecouque, Christophe and De Clercq, Erik and Meng, Ge and Piao, Huri and Chen, Fener},
  title = {Development of fluorine-substituted NH2-biphenyl-diarylpyrimidines as highly potent non-nucleoside reverse transcriptase inhibitors: Boosting the safety and metabolic stability},
  journal = {Acta Pharmaceutica Sinica B},
  year = {2023},
  volume = {13},
  number = {3},
  pages = {1192--1203},
  doi = {10.1016/j.apsb.2022.08.017}
}
Kostenlos starten →